5-Chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine → 4-[N-(4-butylphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridin-5-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine trihydrochloride

Participants

Role	Name	HCID	Charge
Reactant	5-Chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine	HCID 12043486	—
Reactant	4-(4-Butylanilino)-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine	HCID 22557866	—
Product	4-[N-(4-butylphenyl)-N-[[2-(3,4,5-trimethoxyphenyl)pyridin-5-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine trihydrochloride	HCID 22558071	—

Reaction Steps

4-(4-Butylanilino)-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine (147 mg) and 5-chloromethyl-2-(3,4,5-trimethoxyphenyl)pyridine (114 mg) were condensed in the same manner as described in Example 9. The title compound was obtained as yellow powder after converting a free base to a trihydrochloride.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US06605620B1
Source dataset	uspto-grants-2003_08
ORD ID	ord-52a38a2c03e345c1806e2940cc4e52cd
Source note	uspto-grants-2003_08